fidaxomicin 治疗儿童。
Fidaxomicin for the treatment of in children.
机构信息
Department of Medicine, Division of Infectious Diseases, Loyola University Medical Center, Maywood, IL, USA.
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
出版信息
Future Microbiol. 2020 Jul;15(11):967-979. doi: 10.2217/fmb-2020-0104. Epub 2020 Jul 27.
Abstract
Fidaxomicin is an oral narrow-spectrum novel 18-membered macrocyclic antibiotic that was initially approved in 2011 by the US FDA for the treatment of infections (CDI) in adults. In February 2020, the FDA approved fidaxomicin for the treatment of CDI in children age >6 months. In adults, fidaxomicin is as efficacious as vancomycin in treating CDI and reduces the risk of recurrent CDI. An investigator-blinded, randomized, multicenter, multinational clinical trial comparing the efficacy and safety of fidaxomicin with vancomycin in children was recently published confirming similar findings as previously reported in adults. Fidaxomicin is the first FDA-approved treatment for CDI in children and offers a promising option for reducing recurrent CDI in this population.
摘要
非达霉素是一种口服窄谱新型 18 元大环脂类抗生素，最初于 2011 年被美国食品药品监督管理局（FDA）批准用于治疗成人的艰难梭菌感染（CDI）。2020 年 2 月，FDA 批准非达霉素用于治疗 6 个月以上儿童的 CDI。在成人中，非达霉素治疗 CDI 的疗效与万古霉素相当，并降低了复发性 CDI 的风险。最近发表了一项由研究者设盲、随机、多中心、跨国临床试验，比较了非达霉素与万古霉素治疗儿童 CDI 的疗效和安全性，该试验证实了与之前在成人中报告的相似结果。非达霉素是 FDA 批准的首个治疗儿童 CDI 的药物，为减少该人群中复发性 CDI 提供了一种有前景的选择。
相似文献
1
Fidaxomicin for the treatment of in children. fidaxomicin 治疗儿童。
Future Microbiol. 2020 Jul;15(11):967-979. doi: 10.2217/fmb-2020-0104. Epub 2020 Jul 27.
2
Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE). fidaxomicin 和万古霉素治疗儿童和青少年艰难梭菌（梭状芽孢杆菌）感染的安全性和疗效：一项 3 期、多中心、随机、单盲临床试验（SUNSHINE）。
Clin Infect Dis. 2020 Dec 17;71(10):2581-2588. doi: 10.1093/cid/ciz1149.
3
Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. fidaxomicin 与甲硝唑、万古霉素及其联合治疗首发、首次复发和严重艰难梭菌感染的疗效比较：一项观察性队列研究。
Int J Infect Dis. 2021 Feb;103:226-233. doi: 10.1016/j.ijid.2020.11.004. Epub 2020 Nov 11.
4
Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.利奈唑胺：一种新型、窄谱抗菌药物，针对艰难梭菌（梭状芽孢杆菌属）。
Lett Appl Microbiol. 2022 Sep;75(3):526-536. doi: 10.1111/lam.13664. Epub 2022 Feb 11.
5
An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.一项开放性、随机临床试验比较 fidaxomicin 与口服万古霉素治疗同时接受抗生素治疗合并感染的住院患者的艰难梭菌感染。
Clin Infect Dis. 2024 Feb 17;78(2):277-282. doi: 10.1093/cid/ciad606.
6
Is shorter also better in the treatment of Clostridioides difficile infection?在艰难梭菌感染的治疗中，更短的疗程是否更好？
J Antimicrob Chemother. 2024 Jun 3;79(6):1413-1417. doi: 10.1093/jac/dkae119.
7
Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.非达霉素：一种新型的大环内酯类抗生素，用于治疗艰难梭菌感染。
Am J Health Syst Pharm. 2012 Jun 1;69(11):933-43. doi: 10.2146/ajhp110371.
8
Antibiotic Therapies for Clostridioides difficile Infection in Children.儿童艰难梭菌感染的抗生素治疗。
J Pediatric Infect Dis Soc. 2021 Nov 17;10(Supplement_3):S52-S57. doi: 10.1093/jpids/piab059.
9
Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. fidaxomicin 在治疗艰难梭菌感染 (CDI) 期间和之后保留肠道微生物组，并减少毒素再表达和 CDI 的复发。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S132-42. doi: 10.1093/cid/cis338.
10
Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE). fidaxomicin 治疗伴有炎症性肠病、暴发性 CDI、肾功能损害或肝功能损害风险的 CDI 患者：一项常规临床应用回顾性研究（ANEMONE）。
Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2097-2106. doi: 10.1007/s10096-018-3344-1. Epub 2018 Aug 11.
引用本文的文献
1
Gut Microbiota-Gut Metabolites and Infection: Approaching Sustainable Solutions for Therapy.肠道微生物群-肠道代谢产物与感染：寻求可持续的治疗解决方案
Metabolites. 2024 Jan 22;14(1):74. doi: 10.3390/metabo14010074.
本文引用的文献
1
Trends in U.S. Burden of Infection and Outcomes.美国感染负担和结局的趋势。
N Engl J Med. 2020 Apr 2;382(14):1320-1330. doi: 10.1056/NEJMoa1910215.
2
Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Infections.对于患有非重症感染的住院儿童，口服万古霉素可能比甲硝唑能更早缓解症状。
Open Forum Infect Dis. 2019 Nov 14;6(12):ofz492. doi: 10.1093/ofid/ofz492. eCollection 2019 Dec.
3
Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE). fidaxomicin 和万古霉素治疗儿童和青少年艰难梭菌（梭状芽孢杆菌）感染的安全性和疗效：一项 3 期、多中心、随机、单盲临床试验（SUNSHINE）。
Clin Infect Dis. 2020 Dec 17;71(10):2581-2588. doi: 10.1093/cid/ciz1149.
4
Moving the Needle on Clostridioides difficile Research in Children: A Major Step Forward but Challenges Remain.推动儿童艰难梭菌研究取得进展：向前迈出的重要一步，但挑战依然存在。
Clin Infect Dis. 2020 Dec 17;71(10):2589-2591. doi: 10.1093/cid/ciz1154.
5
Natural Clostridioides difficile Toxin Immunization in Colonized Infants.定植婴儿的天然艰难梭菌毒素免疫接种。
Clin Infect Dis. 2020 May 6;70(10):2095-2102. doi: 10.1093/cid/ciz582.
6
U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.2013 年至 2016 年美国基于国家监测的艰难梭菌相关性腹泻分离株对 fidaxomicin 敏感性研究。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00391-19. Print 2019 Jul.
7
Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB.临床艰难梭菌分离株的特征，其对非达霉素的敏感性显著降低，并在 rpoB 中存在 V1143D 突变。
J Antimicrob Chemother. 2019 Jan 1;74(1):6-10. doi: 10.1093/jac/dky375.
8
Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.在日本进行的一项随机、双盲、对照III期研究中，非达霉素治疗艰难梭菌感染的疗效和安全性。
J Infect Chemother. 2018 Sep;24(9):744-752. doi: 10.1016/j.jiac.2018.05.010. Epub 2018 Jun 19.
9
Analysis of Treatment Outcomes for Recurrent Clostridium difficile Infections and Fecal Microbiota Transplantation in a Pediatric Hospital.分析一家儿童医院中复发性艰难梭菌感染和粪便微生物群移植的治疗结果。
Pediatr Infect Dis J. 2019 Jan;38(1):32-36. doi: 10.1097/INF.0000000000002053.
10
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).临床实践指南：成人和儿童艰难梭菌感染：美国传染病学会（IDSA）和美国医疗保健流行病学学会（SHEA） 2017 年更新。
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48. doi: 10.1093/cid/cix1085.
Zotero 插件